Cimerli

Manufacturer:

Coherus Biosciences

Name:

Cimerli

HCPCS Code Descriptor:

Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg

Category:

Q Code

HCPCS:

Q5128

NDC(s):

70114-0441-01, 70114-0440-01

Primary Type:

Opthalmic

Generic/Specialty Status:

LUCENTIS Biosimilar

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About:

Cimerli is an Opthalmic drug manufactured by Coherus Biosciences and administered via the Intraocular route of administration. The Q Code: Q5128 is aligned to the drug Cimerli.

Cimerli can be used to treat eye conditions that involve blood vessel growth under the retina and macula of the eye. Cimerli slows the growth and prevents leakage of abnormal blood vessels that grow in the eye. This medication is manufactured by Coherus Biosciences and is a biosimilar to the medication Lucentis (J2778). Cimerli is aligned to the HCPCS code Q5128, this HCPCS code was aligned to the medication in April 2023. Patient assistance programs for Cimerli can be found through Cimerla Solutions.